MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit covers all individuals and entities who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [8] - The complaint highlights that MoonLake's executives touted SLK's unique clinical advantages without revealing that it targeted the same molecules as UCB's BIMZELX [8] - The stock plummeted 89.9% on September 29, 2025, after the company disclosed that the VELA-2 trial did not achieve statistical significance due to unexpected events in the placebo group [8] Next Steps - Investors who suffered losses and wish to participate in the lawsuit must apply to the Court by December 15, 2025, to be appointed as lead plaintiff [8] - Interested parties can contact Bragar Eagel & Squire, P.C. for more information regarding their rights and the claims [4][5]